Drug Trial Radar · NCT07634367
Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jul 10, 2026
Primary completion
Dec 24, 2027
Study completion Dec 24, 2027
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial evaluates the long-term safety and efficacy of 3 mg HSK39004 Inhalation Suspension administered twice daily for 52 weeks in subjects aged 40 to 80 years with moderate-to-severe stable chronic obstructive pulmonary disease (COPD).
Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
Interventions
HSK39004 Inhalation SuspensionDrug
Dosage Formulation: HSK39004 Inhalation suspension Dosage 3mg; Twice Daily for 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse event (TEAE) incidenceTime frame: From week 1 to week 53
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.